Product Description
Mechanisms of Action: No Mechanism
Novel Mechanism: No
Modality: Large Molecule
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Biostime
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| MVasCDN | N/A |
Unknown status |
Diabetic Nephropathy|Kidney Diseases|Calcinosis|Vascular Calcification |
2020-07-01 |
|
| IRB 2019035 | N/A |
Completed |
Male Breast Cancer |
2019-10-01 |
|
| NCT00970398 | N/A |
Unknown status |
Other |
2012-09-01 |
|
| NCT02029105 | N/A |
Completed |
Mesothelioma |
2010-12-01 |